An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...
Sammy is a lover of all things movies, TV and celebrities. He is currently a Celebrity & Entertainment Writer for TheThings, covering news, reports, features and blog articles. If there’s anything the ...
At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results